Pancreatic Cancer Research

Clinical trialPhase 1 / Phase 2Withdrawn

HepaSphere Interventional Therapy Using Digital Subtraction Angiography(DSA) for Pancreatic Cancer

HepaSphere Interventional Therapy Using Digital Subtraction Angiography(DSA) for Pancreatic Cancer: Clinical Trial

Outcome
Stopped early
Phase
Phase 1 / Phase 2
Status
Withdrawn
Study type
Interventional
Planned start
May 2015
Planned end
June 2020
Enrollment
0 participants
Sites
1
Primary outcomes
Number of participants with Adverse events
Sponsor type
Academic / other
Results posted
No
Last update
12 September 2019

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

The purpose of this study is to evaluate the safety and efficacy of HepaSphere interventional therapy using digital subtraction Angiography(DSA)for pancreatic cancer.

Detailed description public domain (ClinicalTrials.gov)

By enrolling patients with pancreatic cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of HepaSphere interventional therapy using digital subtraction Angiography(DSA)for pancreatic cancer.